Equities analysts predict that Alder Biopharmaceuticals Inc (NASDAQ:ALDR) will announce earnings per share (EPS) of ($0.90) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Alder Biopharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.60) and the lowest estimate coming in at ($1.38). Alder Biopharmaceuticals posted earnings of ($0.91) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 1.1%. The company is expected to report its next earnings report on Monday, November 4th.
According to Zacks, analysts expect that Alder Biopharmaceuticals will report full-year earnings of ($4.13) per share for the current financial year, with EPS estimates ranging from ($5.76) to ($3.32). For the next fiscal year, analysts forecast that the firm will report earnings of ($2.98) per share, with EPS estimates ranging from ($4.63) to ($1.45). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover Alder Biopharmaceuticals.
Alder Biopharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.27.
Several analysts have recently commented on the company. BidaskClub downgraded Alder Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 3rd. Credit Suisse Group reissued a “neutral” rating on shares of Alder Biopharmaceuticals in a research note on Wednesday, July 10th. Zacks Investment Research raised Alder Biopharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $11.00 price objective for the company in a research note on Friday, August 9th. Svb Leerink assumed coverage on Alder Biopharmaceuticals in a research note on Tuesday, May 28th. They issued an “outperform” rating for the company. Finally, Leerink Swann assumed coverage on Alder Biopharmaceuticals in a research note on Tuesday, May 28th. They issued an “outperform” rating and a $21.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Alder Biopharmaceuticals has an average rating of “Buy” and a consensus price target of $16.57.
Shares of Alder Biopharmaceuticals stock opened at $9.74 on Tuesday. The company has a market cap of $721.79 million, a PE ratio of -2.00 and a beta of 2.56. Alder Biopharmaceuticals has a 52 week low of $8.39 and a 52 week high of $18.95. The business has a 50 day moving average price of $9.39 and a 200-day moving average price of $11.51. The company has a quick ratio of 8.94, a current ratio of 8.94 and a debt-to-equity ratio of 1.74.
Several institutional investors and hedge funds have recently modified their holdings of ALDR. Point72 Hong Kong Ltd increased its position in shares of Alder Biopharmaceuticals by 236.9% during the second quarter. Point72 Hong Kong Ltd now owns 3,217 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 2,262 shares during the last quarter. Diamond Hill Capital Management Inc. purchased a new stake in shares of Alder Biopharmaceuticals during the second quarter valued at approximately $126,000. Fulcrum Capital LLC purchased a new stake in shares of Alder Biopharmaceuticals during the second quarter valued at approximately $127,000. Quantamental Technologies LLC purchased a new stake in shares of Alder Biopharmaceuticals during the second quarter valued at approximately $156,000. Finally, Quantitative Systematic Strategies LLC purchased a new stake in shares of Alder Biopharmaceuticals during the second quarter valued at approximately $167,000.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.
Featured Article: Average Daily Trade Volume – What It Means In Stock Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.